Jeffrey M. Holzbeierlein

University of Kansas Medical Center, University of Kansas

Papers

Total Citations

H-Index

About

Dr. Jeffrey M. Holzbeierlein is a leading urologic oncologist whose research focuses on optimizing surgical outcomes for patients with bladder and kidney cancers. His major contributions center on enhancing recovery after radical cystectomy, the complex surgery for bladder cancer. He has been instrumental in demonstrating that Alvimopan, a peripherally acting opioid antagonist, significantly accelerates gastrointestinal recovery and reduces hospital stays for these patients, with his pivotal 2015 study garnering 19 citations. Dr. Holzbeierlein has also advanced the field by comparing robotic versus open partial nephrectomy for kidney cancer, contributing to the shift toward minimally invasive approaches for small renal masses. His recent 2025 work explores the role of patient resilience in improving health-related quality of life after radical cystectomy, highlighting his commitment to holistic patient outcomes. Beyond these studies, he is recognized for integrating enhanced recovery protocols and robotic surgery into standard practice, directly improving morbidity and recovery for thousands of patients. His research consistently bridges surgical innovation with patient-centered care, making him a respected voice in urologic oncology.